The next-generation Cellvizio® platform is now cleared for use with fluorescein dye to image blood flow in the microvasculature and capillaries...
Mauna Kea Technologies today announced second quarter and first half 2021 sales results for the three and six-month periods ended June 30,...
The study combining Cellvizio® with the AQ-Flex™ 19 Confocal Miniprobe™ and the Monarch® Platform from Auris Health, Inc.,...
New peer-reviewed evidence in the prestigious Thorax journal shows lung cancer can be accurately diagnosed with Cellvizio® AQ-Flex™ 19...
New peer-reviewed evidence that Cellvizio can be used as a screening tool in patients with suspected food allergy Mauna Kea...
Launch of the new system is part of the company’s mission to deliver an enhanced platform combining advanced imaging, digital health...
Further validation of how the use of Cellvizio potentially impacts patient management and improves outcomes in multiple gastrointestinal...
Confirming the Role and added value of Cellvizio for the Identification and Management of IBS Patients with Atypical Food Allergies Mauna Kea...
Strong 2H’20 financial results driven by 27% sales growth and a 15% reduction in net loss compared to prior year period The Company...
Mauna Kea Technologies announces today the establishment of an equity financing facility with Kepler Cheuvreux acting as financial intermediary...
Company to host business update conference call on Thursday, April 22, 2021, at 6:00 PM CEST (Paris time) / 12:00 noon (New York time) Mauna...
Evaluating the Role of Cellvizio to Measure Acute and Long-Term Pulmonary Impairment Mauna Kea Technologies is supporting research to...
